M

MannKind Corp
D

MNKD

3.70500
USD
-0.12
(-3.01%)
مغلق
حجم التداول
25,546
الربح لكل سهم
0
العائد الربحي
-
P/E
37
حجم السوق
1,126,071,217
أصول ذات صلة
NEOUSD
NEOUSD
0.01016
(0.18%)
5.54540 USD
C
CYCC
0.06080
(17.37%)
0.41080 USD
E
EKSO
-0.01000
(-0.26%)
3.87000 USD
M
MNKD
-0.11500
(-3.01%)
3.70500 USD
N
NEO
-0.33000
(-4.47%)
7.05000 USD
P
PRTA
0.01500
(0.30%)
5.08500 USD
المزيد
الأخبار المقالات

العنوان: MannKind Corp

القطاع: Healthcare
الصناعة: Biotechnology
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.